Compounds > resveratrol-4'-o-glucuronide
Page last updated: 2024-12-10

resveratrol-4'-o-glucuronide

Description

resveratrol-4'-O-glucuronide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5273284
CHEMBL ID3526962
CHEBI ID175992
MeSH IDM0483531

Synonyms (20)

Synonym
trans-resveratrol 4'-o-glucuronide
(2s,3s,4s,5r,6s)-6-[4-[(e)-2-(3,5-dihydroxyphenyl)ethenyl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
CHEBI:175992
(2s,3s,4s,5r,6s)-6-[4-[(e)-2-(3,5-dihydroxyphenyl)vinyl]phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid
resveratrol metabolite 1
.beta.-d-glucopyranosiduronic acid, 4-[(e)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl
resveratrol-4'-o-glucuronide
387372-20-5
CHEMBL3526962
(2s,3s,4s,5r,6s)-6-{4-[(e)-2-(3,5-dihydroxyphenyl)ethenyl]phenoxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
4-[2-(3,5-dihydroxyphenyl)ethenyl]phenyl hexopyranosiduronic acid
DTXSID80693974
Q27464846
trans resveratrol 4o-b-d-glucuronide
AS-6001
resveratrol-4'-o-d-glucuronide
AKOS037645302
trans-resveratrol 4'-o--d-glucopyranoside
trans-resveratrol 4'-o-?-d-glucuronide
trans-resveratrol-4'-o-d-glucuronide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Synthesis of RES conjugates and development and validation of a sensitive bioanalytical assay were applied to pharmacokinetic evaluation of RES and its circulating monoconjugates in C57BL mice."( Analytical method development for synthesized conjugated metabolites of trans-resveratrol, and application to pharmacokinetic studies.
Canney, DJ; Iwuchukwu, OF; Nagar, S; Sharan, S, 2012)		0.38
" A cellular pharmacokinetic model integrating resveratrol transport/metabolism with glucuronide hydrolysis/excretion was well fitted to the experimental data, allowing derivation of the efflux rate constant values in the absence or presence of shRNA targeting MRP4."( Efflux Transport Characterization of Resveratrol Glucuronides in UDP-Glucuronosyltransferase 1A1 Transfected HeLa Cells: Application of a Cellular Pharmacokinetic Model to Decipher the Contribution of Multidrug Resistance-Associated Protein 4.
Dong, D; Li, F; Quan, E; Wang, S; Wu, B, 2016)		0.43

Bioavailability

ExcerptReferenceRelevance
"Trans-3,5,4'-trihydroxystilbene (trans-resveratrol, RES) exhibits very low bioavailability due to extensive conjugative metabolism."( Analytical method development for synthesized conjugated metabolites of trans-resveratrol, and application to pharmacokinetic studies.
Canney, DJ; Iwuchukwu, OF; Nagar, S; Sharan, S, 2012)		0.38
"Due to the low bioavailability of resveratrol, determining whether its metabolites exert any beneficial effect is an interesting issue."( Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes.
Andrés-Lacueva, C; Churruca, I; Eseberri, I; Lasa, A; Portillo, MP, 2012)		0.38
"Altogether, our data provide significant new insight into the molecular mechanism of RSV and support the notion that despite low bioavailability in vivo, RSV biological effects could be mediated by its metabolites."( Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death.
Aires, V; Cotte, AK; Delmas, D; Ghiringhelli, F; Latruffe, N; Limagne, E, 2013)		0.39
" Its bioavailability is low and raises the possibility that the metabolites of resveratrol have biological effects."( Resveratrol 3-O-D-glucuronide and resveratrol 4'-O-D-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest.
Carew, MA; Carrington, S; Meira, LB; Modjtahedi, H; Polycarpou, E; Tyrrell, E, 2013)		0.39
"Due to the low bioavailability of resveratrol, determining whether its metabolites exert any beneficial effect is an interesting issue."( Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes.
Churruca, I; Eseberri, I; Lasa, A; Portillo, MP, 2013)		0.39
" Indeed, several studies have implicated this bioavailability trait as a major road-block to resveratrol's potential clinical applications."( Toward Resolving the Resveratrol Conundrum: Synthesis and
Adsool, VA; Cui, YT; Goh, YL; Pendharkar, V, 2017)		0.46
" TRG had poor absolute bioavailability in rats."( Pharmacokinetics, tissue distribution and excretion study of trans-resveratrol-3-O-glucoside and its two metabolites in rats.
Dong, C; Su, M; Wan, J; Zhou, M, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1430694Drug level in human hepatocytes treated with resveratrol at 5 uM by LC-MS/MS analysis2017ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5
Toward Resolving the Resveratrol Conundrum: Synthesis and
AID1884061Antibacterial activity against Staphylococcus aureus LMG 10147 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884068Antibacterial activity against Clostridium tetani CECT 4629 incubated for 24 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884066Antibacterial activity against Clostridium-ihumii AP5 incubated for 24 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884062Antibacterial activity against Staphylococcus aureus LMG 15975 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1220757AUC (0 to t) in C57BL/6 mouse treated with 5 mg/kg of resveratrol-3-glucuronide administered intraarterially by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.
AID1884053Antibacterial activity against Bacillus cereus ATCC 14579 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1220768AUC (0 to infinity) in C57BL/6 mouse treated with 15 mg/kg of trans-3,5,4'-Trihydroxystilbene [trans-resveratrol] administered intraarterially by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.
AID1884056Antibacterial activity against Enterococcus faecalis LMG 16216 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884067Antibacterial activity against Clostridium perfringens CECT376 incubated for 24 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884059Antibacterial activity against Enterococcus faecalis LMG 16003 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1220758AUC (0 to infinity) in C57BL/6 mouse treated with 5 mg/kg of resveratrol-3-glucuronide administered intraarterially by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.
AID1884069Antimicrobial activity against Escherichia coli LMG 8224 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884060Antibacterial activity against Staphylococcus aureus LMG 8224 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884054Antibacterial activity against Bacillus cereus ATCC 10987 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884065Antibacterial activity against Clostridium difficile CECT531 incubated for 24 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1220767AUC (0 to t) in C57BL/6 mouse treated with 15 mg/kg of trans-3,5,4'-Trihydroxystilbene [trans-resveratrol] administered intraarterially by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.
AID1884063Antibacterial activity against Clostridium beijerinckii B504 incubated for 24 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884055Antibacterial activity against Enterococcus faecalis LMG 08222 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884057Antibacterial activity against Enterococcus faecalis V583 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1220759Terminal half life in C57BL/6 mouse treated with 5 mg/kg of resveratrol-3-glucuronide administered intraarterially by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.
AID1220769Terminal half life in C57BL/6 mouse treated with 15 mg/kg of trans-3,5,4'-Trihydroxystilbene [trans-resveratrol] administered intraarterially by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Oct, Volume: 40, Issue:10
In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.
AID1884058Antibacterial activity against Enterococcus faecalis LMG 11423 incubated for 20 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
AID1884064Antibacterial activity against Clostridium botulinum CECT551 incubated for 24 hrs by CLSI based broth microdilution method2022Journal of natural products, 06-24, Volume: 85, Issue:6
Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (7.69)29.6817
2010's22 (84.62)24.3611
2020's2 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.89 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.85%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbonyl cyanide m-chlorophenyl hydrazone
Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.		3.5110hydrazone;
monochlorobenzenes;
nitrile		antibacterial agent;
geroprotector;
ionophore
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		3.5110aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		3.5110glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.7630D-glucopyranoseepitope;
mouse metabolite
gentamicin c1a
[no description available]		3.5110gentamycin C
dihydroresveratrol
dihydroresveratrol: structure in first source. dihydroresveratrol : A stilbenol that is 1,1'-ethane-1,2-diyldibenzene with hydroxy groups at positions 1, 3 and 4'.		2.1510stilbenolplant metabolite;
xenobiotic metabolite
glycogen
glycogen : A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues.		2.4110
puromycin
[no description available]		2.1510puromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		9.05242resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		7.94242stilbene
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		2.1310aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
astringin
astringin: structure in first source. trans-astringin : A stilbenoid that is piceatannol substituted at position 3 by a beta-D-glucosyl residue.		2.0510beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		antineoplastic agent;
antioxidant;
metabolite
4,4'-dihydroxystilbene
[no description available]		2.0510stilbene-4,4'-diol
3,5,4'-trihydroxystilbene-4'-o-glucoside
trans-resveratrol-4'-O-beta-D-glucopyranoside: structure in first source		2.0510
lisinopril
Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.		2.1310dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
3,4',5-trimethoxystilbene
3,4',5-trimethoxystilbene: structure in first source		3.5110
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		2.0810
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.0210purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
leptin
Leptin: A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.7830
Colonic Neoplasms
Tumors or cancer of the COLON.		02.7830
Extravascular Hemolysis
[description not available]		02.0810
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.0810
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.110
Alloxan Diabetes
[description not available]		02.110
Autoimmune Diabetes
[description not available]		02.110
Cardiac Diseases
[description not available]		02.110
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.110
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		02.110
Hepatocellular Carcinoma
[description not available]		02.110
Cancer of Liver
[description not available]		02.110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.110
Breast Cancer
[description not available]		02.5220
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.5220
Colicky Pain
[description not available]		07.4844
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		07.4844
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		07.4844
Abdominal Pain
Sensation of discomfort, distress, or agony in the abdominal region.		07.4844
HIV Coinfection
[description not available]		02.0210
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.0210
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0210
chemdatabank.com